Enclomiphene Citrate Safety Signals & FDA Actions: A Clinical Deep Dive

What Is Enclomiphene Citrate and How Does It Work?

Enclomiphene is the trans-geometric isomer of the racemic SERM clomiphene citrate. It acts as a competitive antagonist at hypothalamic estrogen receptors, removing the negative-feedback signal that estradiol normally exerts on gonadotropin-releasing hormone (GnRH) pulse frequency. The resulting rise in GnRH drives pituitary LH and FSH secretion, which in turn stimulates Leydig cell testosterone synthesis and maintains Sertoli cell support of spermatogenesis. This differentiates it sharply from exogenous testosterone, which suppresses the HPG axis and typically reduces sperm counts within weeks.

The Two Isomers of Clomiphene

Racemic clomiphene contains approximately 38% enclomiphene (trans) and 62% zuclomiphene (cis). Zuclomiphene has a much longer half-life (several weeks) and behaves as a partial estrogen agonist at certain receptor subtypes, contributing to the visual and mood side effects seen with racemic clomiphene [1]. Isolating enclomiphene was intended to preserve the testosterone-raising benefit while reducing the adverse-effect burden attributed to the cis-isomer [2].

Receptor Pharmacology

Enclomiphene binds ER-alpha with high affinity and acts as an antagonist in hypothalamic tissue. At the pituitary level, the antagonism of estrogen-mediated negative feedback allows sustained gonadotropin secretion. LH rises within 24 to 48 hours of the first dose in most men with secondary hypogonadism [3]. FSH follows a similar trajectory, which is the mechanistic basis for the fertility-preservation advantage cited in Kim et al. [4].

Half-Life and Dosing Kinetics

Enclomiphene's plasma half-life is roughly 10 hours, considerably shorter than zuclomiphene's multi-week accumulation. This means steady-state is reached within two to three days, and washout after discontinuation is relatively rapid. Compounded preparations are typically dispensed as 12.5 mg or 25 mg oral capsules dosed once daily in the morning.

Clinical Trial Evidence for Efficacy

Kim et al. 2016 (BJU International)

The most-cited controlled data come from Kim et al. (BJU Int 2016, N=12), a randomized crossover study comparing enclomiphene to testosterone gel in men with secondary hypogonadism [4]. Mean total testosterone rose from below 300 ng/dL at baseline to above 400 ng/dL on enclomiphene, while sperm concentration either held steady or improved. In the testosterone-gel arm, sperm concentration dropped by a mean of 24% at 3 months, consistent with HPG-axis suppression. This 12-person study is small, which limits statistical confidence, but the directional findings are biologically coherent and have been cited in subsequent review literature [5].

Repros Therapeutics Phase III Data (Androxal)

Repros Therapeutics conducted three Phase III trials (ZA-304, ZA-201, and the CAMBREX study) in support of the Androxal NDA between 2010 and 2013 [6]. Across those trials, enclomiphene 12.5 mg and 25 mg produced mean morning testosterone levels above 300 ng/dL in roughly 74% to 80% of participants at 3 months. Sperm concentration was maintained or increased in the enclomiphene arms versus a consistent decline in the comparator testosterone-gel arms. The FDA's Complete Response Letters, however, cited insufficient data on long-term cardiovascular outcomes, bone density, and sexual function as barriers to approval [7].

Ramasamy et al. 2014 (BJU International)

Ramasamy et al. (BJU Int 2014) reported that in 36 men with secondary hypogonadism, enclomiphene 12.5 mg daily for 3 months raised mean total testosterone from 218 ng/dL to 399 ng/dL [5]. LH increased from 3.1 mIU/mL to 7.6 mIU/mL and FSH from 3.4 mIU/mL to 5.9 mIU/mL, confirming the hypothalamic mechanism of action [5]. No serious adverse events were reported in this short-duration cohort.

FDA Regulatory History and Rejection Rationale

First Complete Response Letter (2013)

Repros Therapeutics submitted the original Androxal NDA in 2012. The FDA issued a Complete Response Letter in early 2013 [7]. The agency's primary objections centered on:

1. Absence of cardiovascular outcomes data. At the time, the FDA was intensifying scrutiny of all testosterone-class therapies following an interim analysis of the Testosterone in Older Men with Mobility Limitations (TOM) trial, which was stopped early due to a higher rate of cardiovascular events on testosterone [8].
2. Insufficient bone mineral density data. Secondary hypogonadism is associated with reduced BMD, and the agency wanted evidence that enclomiphene could normalize testosterone long enough to benefit bone.
3. Inadequate characterization of the long-term safety profile beyond 3 months.

Second Complete Response Letter (2016)

Repros resubmitted with additional Phase III data and was issued a second Complete Response Letter in 2016 [7]. The FDA again requested longer-duration trials and specifically flagged the absence of a dedicated cardiovascular outcomes trial in line with the 2010 FDA guidance requiring safety studies for testosterone products [9]. Following the second rejection, Repros Therapeutics effectively ceased development of Androxal, and the company was subsequently acquired.

Current US Legal Status

No FDA-approved enclomiphene product exists as of 2025. Compounding pharmacies operating under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act may prepare enclomiphene for individual patients when a licensed prescriber issues a valid prescription. The FDA has not placed enclomiphene on the "Difficult to Compound" list or on the list of bulk drug substances that may not be used in compounding, meaning its compounded status is currently permitted [10]. However, compounded preparations are not subject to the same manufacturing-consistency standards as FDA-approved drugs.

Safety Signals: What the Evidence Shows

Thromboembolic Risk

Clomiphene-class SERMs carry a recognized thromboembolic risk mediated through effects on coagulation factors, particularly reductions in protein S and increases in Factor VII activity [11]. The FDA's label for racemic clomiphene lists thromboembolism as a known adverse effect. Enclomiphene-specific thromboembolism data are limited to the Repros Phase III population (total exposure approximately 400 patient-years), in which venous thromboembolic events were rare but present [6]. Prescribers should screen for personal or family history of DVT, PE, or known thrombophilia before initiating enclomiphene.

Visual Disturbances

Blurred vision and other visual symptoms are well-documented with racemic clomiphene. These are attributed primarily to the zuclomiphene isomer's partial agonist activity at retinal ER receptors. Enclomiphene's shorter half-life and absence of the cis-isomer suggest a lower burden of visual side effects, and the Repros Phase III data showed a lower incidence than historical racemic clomiphene rates [6]. Persistent or worsening visual symptoms warrant prompt ophthalmology referral and discontinuation.

Mood and Psychiatric Effects

A subset of men on enclomiphene report irritability, mood fluctuations, and sleep disruption during the first four to six weeks of therapy [5]. These effects may reflect estrogenic receptor antagonism in limbic tissue. They are typically transient and dose-dependent. Patients with a history of depression or anxiety should be monitored more closely during the titration phase.

Estradiol Elevation

Because enclomiphene raises testosterone, aromatization to estradiol increases proportionally. Estradiol levels above 40 pg/mL in men can contribute to gynecomastia, water retention, and libido changes [12]. Baseline and follow-up estradiol measurement is standard of care. Some prescribers co-administer anastrozole 0.5 mg twice weekly if estradiol rises above 50 pg/mL, though this approach is not supported by RCT-level evidence specifically for enclomiphene.

Cardiovascular Data Gap

The single most significant safety concern raised by the FDA is the absence of long-term cardiovascular outcome data. The 2010 FDA guidance on testosterone products mandated that manufacturers conduct cardiovascular outcomes trials [9]. The TRAVERSE trial (N=5,246, mean follow-up 33 months), published in the New England Journal of Medicine in 2023, specifically evaluated testosterone replacement therapy and found no significant increase in major adverse cardiovascular events versus placebo in men with hypogonadism and elevated cardiovascular risk [13]. Enclomiphene has no comparable trial. Whether the mechanism of action, raising endogenous testosterone rather than delivering exogenous hormone, translates to a different cardiovascular risk profile remains unstudied at the scale required for regulatory approval.

Lipid and Metabolic Effects

SERMs can affect hepatic lipid metabolism. Racemic clomiphene has been associated with modest reductions in HDL in some cohorts [11]. Enclomiphene-specific lipid data from the Repros trials showed no consistent adverse lipid signal at 3 months, but the study duration is too short to draw conclusions about atherogenic risk [6]. A fasting lipid panel at baseline and at 3 months is advisable.

Enclomiphene vs. Exogenous Testosterone: Clinical Decision Points

Choosing between enclomiphene and FDA-approved testosterone replacement therapy (TRT) depends on fertility goals, symptom severity, and risk tolerance. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend against the routine use of testosterone therapy in men who are currently desiring fertility" and endorses gonadotropin-based or SERM-based strategies as alternatives [14]. Enclomiphene fits squarely in the SERM-based category, but prescribers should note the guideline was written before the FDA rejections were final, and the guideline does not specifically endorse enclomiphene by name.

When Enclomiphene May Be Preferred

Men under 45 with secondary hypogonadism, active fertility intent, BMI <35, and testosterone between 200 and 350 ng/dL represent the population most likely to respond to enclomiphene and least likely to need the more reliable testosterone normalization that TRT provides. A short trial of 12 weeks is a reasonable diagnostic and therapeutic window.

When TRT Is Likely the Better Choice

Men with primary hypogonadism (elevated LH and FSH at baseline) will not respond to enclomiphene, because the HPG axis is already maximally stimulated. Men with testosterone below 150 ng/dL, significant anemia, or severe osteoporosis may need the more predictable hormone delivery of injectable or topical TRT. The TRAVERSE trial provides the most recent reassurance on TRT's cardiovascular safety in a high-risk cohort [13].

Monitoring Protocol

A practical monitoring schedule for enclomiphene:

• Baseline: total testosterone (morning, fasting), LH, FSH, estradiol, PSA if age above 40, CBC, lipid panel, BMI
• Week 6 to 8: total testosterone, estradiol, LH
• Week 12: full panel including FSH, CBC, lipid panel
• Ongoing every 6 months if stable

Compounding Considerations and Quality Concerns

Because enclomiphene is available only through compounding pharmacies in the United States, product quality varies. A 2017 FDA survey of compounded hormone preparations found that roughly 34% of sampled products failed potency specifications [15]. Prescribers should direct patients to 503B outsourcing facilities with current USP <795> and USP <797> compliance, third-party certificate of analysis (COA) documentation, and sterility testing for any injectable preparations.

The FDA has not published specific guidance on enclomiphene compounding beyond the general framework of the Drug Quality and Security Act of 2013. Practitioners operating within telehealth platforms should document the medical necessity of compounded enclomiphene in the patient record, referencing the absence of an FDA-approved alternative and the patient's fertility-preservation goals.

Mechanism Summary: Why Enclomiphene Raises Testosterone Without Suppressing Sperm

The pituitary-gonadal axis in a healthy adult male operates through a classic negative-feedback loop. Testosterone and estradiol reach the hypothalamus, suppress GnRH pulse amplitude and frequency, and thereby limit LH and FSH release. Exogenous testosterone, injected or absorbed transdermally, floods this loop with supraphysiologic steroid signal, which shuts down GnRH pulsatility entirely within 30 to 90 days. Sperm production depends on high intratesticular testosterone concentrations maintained by LH-driven Leydig cell activity and on FSH-driven Sertoli cell function. Both are lost within 3 months of TRT in a majority of men [16].

Enclomiphene occupies hypothalamic ER-alpha sites without activating them, effectively blinding the feedback sensor to circulating estradiol. GnRH pulses normalize or increase, LH rises within 48 hours, Leydig cells produce more testosterone, and Sertoli cells continue to receive FSH support. The net result is a testosterone level in the eugonadal range with an intact, functioning HPG axis. This is why Kim et al. Found that sperm concentration was maintained in the enclomiphene arm while it dropped measurably in the testosterone-gel arm over the same 3-month period [4].